http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Pfizer (PFE), BioNTech (BNTX) Starts Trial to Evaluate COVID-19 Vaccine in Pregnant Women
-
Pfizer and BioNTech Commence Global Clinical Trial to Evaluate COVID-19 Vaccine in Pregnant Women
-
In Vitro Study Published in NEJM Demonstrates Sera from Individuals Immunized with the Pfizer (PFE) -BioNTech (BNTX) COVID-19 Vaccine Neutralize SARS-CoV-2 with South African Variant Spike Mutations
-
In Vitro Study Published in The New England Journal of Medicine Demonstrates Sera from Individuals Immunized with the Pfizer-BioNTech COVID-19 Vaccine Neutralize SARS-CoV-2 with South African Variant
-
Myovant Sciences (MYOV), Pfizer (PFE) Announce Publication in NEJM of Phase 3 LIBERTY Studies of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids
-
Myovant Sciences and Pfizer Announce Publication in the New England Journal of Medicine of Phase 3 LIBERTY Studies of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids
-
Myovant Sciences and Pfizer Announce Publication in the New England Journal of Medicine of Phase 3 LIBERTY Studies of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids
-
Pfizer (PFE) Initiates Pivotal Phase 2 MagnetisMM-3 Trial of BCMA-CD3 Bispecific Antibody Elranatamab (PF-06863135) in Multiple Myeloma
-
Pfizer Initiates Pivotal Phase 2 MagnetisMM-3 Trial of BCMA-CD3 Bispecific Antibody Elranatamab (PF-06863135) in Multiple Myeloma
-
Pfizer (PFE) and BioNTech (BNTX) to Supply European Union with 200 Million Additional Doses of COVID-19 Vaccine
-
Pfizer and BioNTech to Supply the European Union with 200 Million Additional Doses of COMIRNATY®
-
Pfizer and BioNTech to Supply the European Union with 200 Million Additional Doses of COMIRNATY®
-
U.S. FDA Approves PANZYGA® for the Treatment of Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
-
Pfizer (PFE), BioNTech (BNTX) to Supply the United States with 100 Million Additional Doses of COVID-19 Vaccine
-
Pfizer and BioNTech to Supply the United States with 100 Million Additional Doses of COVID-19 Vaccine
-
Nextech AR’s Virtual Event Platform Selected by Canadian Surgery Forum for Its 2021 Virtual Trade Show
-
Pfizer (PFE) Confirms U.S. Patent Term Extension for IBRANCE (palbociclib) Until March 2027
-
Pfizer Confirms U.S. Patent Term Extension for IBRANCE® (palbociclib) Until March 2027
-
Pfizer (PFE) and BioNTech (BNTX) Publish Preclinical Data from Investigational COVID-19 Vaccine Program in Nature
-
Pfizer and BioNTech Publish Preclinical Data from Investigational COVID-19 Vaccine Program in Nature
-
Pfizer (PFE) Shares Co-Primary Endpoint Results from Post-Marketing Required Safety Study of XELJANZ in Subjects with RA
-
Pfizer Shares Co-Primary Endpoint Results from Post-Marketing Required Safety Study of XELJANZ® (tofacitinib) in Subjects with Rheumatoid Arthritis (RA)
-
Myovant Sciences (MYOV) , Pfizer (PFE) Announce Positive One-Year Data from Phase 3 SPIRIT Extension Study of Once-Daily Relugolix Combination Therapy in Women with Endometriosis
-
Myovant Sciences and Pfizer Announce Positive One-Year Data from Phase 3 SPIRIT Extension Study of Once-Daily Relugolix Combination Therapy in Women with Endometriosis
-
Myovant Sciences and Pfizer Announce Positive One-Year Data from Phase 3 SPIRIT Extension Study of Once-Daily Relugolix Combination Therapy in Women with Endometriosis
-
Pfizer (PFE) and EMD Serono Report European Commission Approves BAVENCIO (avelumab) for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma
-
European Commission Approves BAVENCIO® (avelumab) for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma
-
Pfizer (PFE), BioNTech (BNTX) Reach Agreement with COVAX for Advance Purchase of Vaccine to Help Combat COVID-19
-
Pfizer and BioNTech Reach Agreement with COVAX for Advance Purchase of Vaccine to Help Combat COVID-19
-
Pfizer (PFE), BioNTech (BNTX) Publish Results of Study Showing COVID-19 Vaccine Elicits Antibodies that Neutralize Pseudovirus Bearing the SARS-CoV-2 U.K. Strain Spike Protein in Cell Culture
-
Pfizer and BioNTech Publish Results of Study Showing COVID-19 Vaccine Elicits Antibodies that Neutralize Pseudovirus Bearing the SARS-CoV-2 U.K. Strain Spike Protein in Cell Culture
-
Pfizer (PFE) Announces XALKORI Approved by FDA for ALK-positive Anaplastic Large Cell Lymphoma in Children and Young Adults
-
Pfizer’s XALKORI® (crizotinib) Approved by FDA for ALK-positive Anaplastic Large Cell Lymphoma in Children and Young Adults
-
PureTech (PRTC) Founded Entity Vedanta Biosciences Announces $25 Million Investment from Pfizer Inc.
-
PureTech Founded Entity Vedanta Biosciences Announces $25 Million Investment from Pfizer Inc.
-
Pfizer Invests $120 Million in Biotechnology Innovation Through the Pfizer Breakthrough Growth Initiative
-
Pfizer (PFE), BioNTech SE (BNTX) Study Shows its COVID-19 Vaccine Works on More Contagious U.K. Strain
-
An In Vitro Study Shows Pfizer-BioNTech COVID-19 Vaccine Elicits Antibodies that Neutralize SARS-CoV-2 with a Mutation Associated with Rapid Transmission
-
Pfizer (PFE) Doses First Participant in Phase 3 Study for Duchenne Muscular Dystrophy Investigational Gene Therapy
-
Pfizer Doses First Participant in Phase 3 Study for Duchenne Muscular Dystrophy Investigational Gene Therapy
-
Dewpoint Announces Collaboration with Pfizer to Develop Potential Therapies for a Rare Form of Muscular Dystrophy
-
Pfizer Invites Public to Listen to Two Webcasts of Pfizer Discussions at Healthcare Conference
-
Pfizer (PFE), OPKO Health (OPK) Announce FDA Accepts Regulatory Submission for Review of Somatrogon to Treat Pediatric Patients with Growth Hormone Deficiency
-
US FDA Accepts Regulatory Submission from Pfizer and OPKO for Review of Somatrogon to Treat Pediatric Patients with Growth Hormone Deficiency
-
Pfizer (PFE), BioNTech (BNTX) to Supply the European Union with 100 Million Additional COVID-19 Vaccine Doses
-
Pfizer and BioNTech to Supply the European Union with 100 Million Additional Doses of COMIRNATY®
-
Pfizer and BioNTech to Supply the European Union with 100 Million Additional Doses of COMIRNATY®
-
LORBRENA® (lorlatinib) sNDA in Previously Untreated ALK-Positive Lung Cancer Accepted for Priority Review by U.S. FDA
-
UPDATE - Sumitovant Biopharma Announces Myovant Sciences and Pfizer Enter Collaboration to Develop and Commercialize Relugolix in Oncology and Women’s Health
-
Sumitovant Biopharma Announces Myovant Sciences and Pfizer Enter Collaboration to Develop and Commercialize Relugolix in Oncology and Women’s Health

